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Myopathological features in skeletal muscle of patients with chronic obstructive
pulmonary disease. H.R. Gosker, B. Kubat, G. Schaart, G.J. van der Vusse, E.F.M.
Wouters, A.M.W.J. Schols. #ERS Journals Ltd 2003.
ABSTRACT: Despite the fact that muscle weakness is a major problem in chronic
obstructive pulmonary disease (COPD), detailed information on myopathological
changes at the microscopic level in these patients is scarce, if indeed available at all.
Vastus lateralis biopsies of 15 COPD weight-stable patients (body mass index (BMI)
23.9¡1.0 kg?m-2; fat-free mass index (FFMI) 17.2¡1.7 kg?m-2) and 16 healthy age-
matched controls (BMI 26.3¡0.8 kg?m-2; FFMI 19.6¡2.2 kg?m-2) were evaluated.
Histochemistry was used to evaluate myopathological features. Immunohisto-
chemistry was used for the detection of macrophages and leukocytes, and active
caspase 3 and terminal deoxynucleotidyl transferase deoxyuridine triphosphate
(dUTP) nick-end labelling (TUNEL) as markers of apoptosis.
Fatty cell replacement and fibrosis were observed in both groups, the latter being
slightly, but significantly, more pronounced in COPD. No differences between COPD
and controls were found with respect to central nuclei, necrosis, regeneration, or fibre
splitting. Signs of mitochondrial abnormalities were absent and normal numbers of
inflammatory cells were found. Active caspase 3 positive myocytes were not observed
and no difference was found in the number of TUNEL-positive myonuclei between
controls and COPD patients (1.1% versus 1.0%, respectively). The cross-sectional area
of type-IIX muscle fibres was smaller in COPD than in controls (2,566 versus
4,248 mm2).
Except for the I to IIX shift in fibre types, the selective type-IIX atrophy and a slight
accompanying increase in fibrosis and fat cell replacement in chronic obstructive
pulmonary disease relative to age-matched controls, no other morphological
abnormalities were observed in the muscle biopsies of chronic obstructive pulmonary
disease patients. Also, in this group of clinically and weight stable chronic obstructive
pulmonary disease patients, apoptosis appeared not to be involved in muscle pathology.
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Peripheral muscle weakness is a major problem in chronic
obstructive pulmonary disease (COPD) [1, 2], contributing to
exercise intolerance [3] and, hence, to a decreased health
status [4]. The loss of muscle mass has been well described in
these patients [1, 2], but surprisingly, little data are reported
regarding the morphology of limb muscles in COPD. First,
muscle weakness has long been ignored, since studies focused
primarily on the ventilatory limitations of exercise capacity.
Secondly, those studies that did describe intrinsic muscular
abnormalities in COPD tended to focus primarily on muscle
fibre-type distributions and fibre sizes or dealt with molecular
and biochemical alterations [5]. Thus, a complete pathological
picture of the changes in limb muscle of patients with COPD
is not yet available, whereas the microscopic examination of
muscle biopsies is a first crucial step to enlarge the under-
standing of the underlying pathology in the peripheral
muscles of COPD patients.
It is beyond the scope of this paper to describe all the
different types of myopathies (for a review see PEARSON and
YOUNG [6]), but the parameters that are being used to screen
the muscle may prove very helpful in the examination of
myopathological features in the diseased muscle of COPD
patients. In general, anybody suffering from severe peripheral
muscle weakness will be referred to a pathologist or
neurologist to assess the type and extent of the muscle
pathology. The first step in the assessment of a peripheral
muscle biopsy is to determine whether any abnormalities are
present, and, if any, to determine if these changes are
neurogenic, myopathic or inflammatory [7]. Neurogenic
changes are characterised by fibre atrophy of both fibre
types and the angular form of the atrophied fibres. Fibre type
grouping occurs when reinnervation takes place. Nuclear
clumps are the end products of very severe atrophy. In the
mitochondrial enzyme staining moth-eaten fibres may be
found. Fibrosis and replacement of myocytes by fat cells
occurs in longstanding and substantial atrophy. In the second
group, i.e. myopathies, increased variation of fibre size is not
unusual, with atrophy and compensatory hypertrophy, the
atrophied fibres are predominantly rounded and atrophy
tends to be fibre-type specific (commonly type-I fibres),
centralisation of the nuclei is often present and there is no
fibre-type grouping. Fibrosis and fatty cell replacement of
muscle tissue occurs especially in dystrophies (these could be
defined as a severe and well defined subgroup of myopathies).
The third group are the inflammatory muscle diseases, i.e.
myositis, characterised by inflammatory infiltration and more
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or less pronounced necrosis, myolysis and regeneration of
muscle fibres. Depending on the extent of muscle destruction,
fibrosis may occur in the late stages.
The aim of the current study was to provide a detailed
picture of skeletal muscle pathology in COPD, in order to
gain more insight in the process of muscle wasting in these
patients. For this purpose, muscle biopsies from the vastus
lateralis of patients with COPD and healthy age-matched
control subjects were examined. Microscopic evaluations were
performed by means of standard histochemical techniques.
Myopathological features were evaluated by an expert
pathologist. In addition, inflammatory cells and apoptosis
were evaluated immunohistochemically.
Methods
A group of 15 patients with moderate-to-severe airflow
obstruction (aged 42–76 yrs) and 16 healthy age-matched
volunteers (aged 60–70 yrs) was studied. All patients had
COPD according to American Thoracic Society guidelines [8]
and chronic airflow limitation, defined as measured forced
expiratory volume in one second (FEV1) v70% of reference
FEV1. Furthermore, patients had irreversible obstructive
airway disease (v10% improvement of FEV1 predicted
baseline after b2-agonist inhalation). They were in a clinically
stable condition and not suffering from a respiratory tract
infection or an exacerbation of their disease at least 4 weeks
prior to the study. Altogether, seven COPD patients were on
a maintenance dose (5–10 mg?day-1) of prednisolone. Exclu-
sion criteria were malignancy, cardiac failure, distal arterio-
pathy, recent surgery, severe endocrine, hepatic or renal
disorders, and use of anticoagulant medication. The healthy
age-matched control subjects were volunteers recruited
through an advertisement in a local newspaper. They under-
went a physical examination by a physician to ensure that
they were free from significant pulmonary or cardiac disease.
Written informed consent was obtained from all subjects
and the study was approved by the medical ethical committee
of the University Hospital Maastricht (Maastricht, the
Netherlands).
Pulmonary function tests
All patients and control subjects underwent spirometry to
determine, amongst other measurements, FEV1, with the
highest value from at least three technically acceptable
assessments being used. Residual volume and intrathoracic
gas volume were assessed by whole-body plethysmography and
diffusion capacity for carbon monoxide was measured by using
the single-breath method (Masterlab; Jaeger, Wurzburg,
Germany). All values obtained were expressed as percent-
age of the predicted value [9]. Arterial oxygen tension was
determined (ABL 330; Radiometer, Copenhagen, Denmark)
in a blood sample from the radial artery while subjects breathed
room air.
Assessment of body composition
Body height was determined to the nearest 0.5 cm and body
weight was assessed to the nearest 0.1 kg while subjects wore
light clothing and no shoes. Fat-free mass (FFM) was
determined by scanning subjects on a DPX bone densitometer
(Lunar Radiation Corporation, Madison, WI, USA) as
described previously [10]. Weight parameters were adjusted
for body surface, resulting in the BMI and FFM index
(FFMI) [11].
Assessment of muscle function
Isometric handgrip strength was assessed in all subjects by
using a Harpenden handgrip dynamometer (Yamar; Preston,
Jackson, MI, USA). Linear isokinetic muscle function of the
lower limbs was assessed by a multijoint dynamometer device
(Aristokin; Lode, Groningen, the Netherlands) at 20 cm?s-1
and at 60 cm?s-1 as described previously [2]. At a speed of
20 cm?s-1, the maximal power generated by the legs mainly
determined the outcome of performance. At a speed of
60 cm?s-1 performance is also influenced by muscle coordination.
Before testing, each subject was familiarised in a standardised
way with the equipment and the requested movement.
Collection and processing muscle tissue
Postabsorptive muscle biopsies of the vastus lateralis were
obtained by the needle biopsy technique [12]. The specimen
was frozen in melting isopentane precooled in liquid nitrogen
and stored at -35uC. The examination of muscle morphology
was performed on serial cryostat cross-sections, of 10 mm
thickness. General muscle architecture and fibre morphology
were shown by routine haematoxylin-eosin (H&E) staining or
van Gieson staining (for additional collagen staining).
Muscle-fibre typing and distribution (fibre types I, IIA and
IIX) were evaluated by myofibrillar adenosine triphospho-
tease (mATPase) staining and immunohistochemistry as
described previously. The combined staining results of the
three different mATPase stainings (one with pre-incubation at
pH 4.4, one at pH 10.4, and double pre-incubation at
pH 10.4 followed by 4.6) with three antibodies against
myosine heavy chain (MyHC) isoforms (anti-type I MyHC
(mAb 219-1D1), anti-type IIA MyHC (mAb 333-7H1) and
anti-types IIAzIIX MyHC (mAb 332-3D4)) and at least 100
(but mostly up to 200) fibres were analysed [13]. Fibre cross-
sectional area (CSA) and roundness (values ranging 0–1, with
1 being perfectly round) were measured with an interactive
image analysis system (Leica QWin Image Analysis System;
Leica Microsystems BV, Rijswijk, the Netherlands) [14].
Cytochrome c oxidase (COX) and succinate dehydrogenase
(SDH) staining was performed as described previously [13].
The altered muscle fibre-type distribution, metabolic profile
and reduced fibre type IIX CSA shown in table 1 have been
reported earlier [13, 14]. Deoxyribonucleic acid (DNA)
fragmentation in muscle-fibre nuclei was detected by terminal
deoxynucleotidyl transferase dUTP nick end labelling
(TUNEL) after pretreatment with proteinase K for 5 min,
followed by diaminobenzidine staining with a peroxidase
conjugated antibody (TdT-FragELTM DNA Fragmentation
Detection Kit, Oncogene Research Products, Boston, MA,
USA). Altogether, 300–500 myocyte nuclei were counted
using a grid and the percentage of positive nuclei was
determined. A common problem of the TUNEL reaction is
the weak background staining of nuclei. Therefore as
TUNEL-positive control, muscle sections were treated with
1 mg?mL-1 deoxyribonucleic (DNase) I, to obtain DNA
fragmentation. The staining intensity in these nuclei served
as positive controls. Active caspase 3 was evaluated by
immunostaining with the polyclonal anti-active caspase 3
antibody CM1 (Idun Pharmaceuticals, La Jolla, CA, USA).
Mouse monoclonal antibodies were used for identification of
leukocytes (anti-leukocyte common antigen CD45, M0701;
Dako Ltd, High Wycombe, UK) and macrophages
(anti-CD68, M0814; Dako). Primary antibody binding was
detected with the StreptABComplex/HRP method (K0377;
Dako) and staining with diaminobenzidine. Cryosections
of a human malignant sarcoma and human tonsil were
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used as a positive control for active caspase 3, and leuko-
cytes/macrophages, respectively. In TUNEL, active caspase
3, leukocyte, and macrophage staining nuclei were counter-
stained with haematoxylin. The following features were
evaluated semi-quantitatively: 1) inflammatory infiltrates,
fibrosis, fatty cell replacement, fibre splitting, vacuoles,
necrosis, regeneration, hyaline and ring fibres, and central
nuclei (H&E); 2) mitochondrial rearrangements, such as
subsarcolemmal accumulation, targets, moth-eaten fibres and
cores (COX and SDH); and 3) fibre-type distribution and
grouping, and atrophied/hypertrophied fibres (mATPase).
This screening was performed in a blinded manner by an
expert pathologist who assigned scores ranging 0–5 indicating
the severity of each feature, 0 for the absence of the feature,
5 for severe abnormalities.
Statistical analysis
Data were analysed with the unpaired t-test (corrected for
unequal variances if required), Pearson Chi-squared test, or
the Pearson correlation test [15]. Analysis of covariance with
sex as covariate was used to compare leg power between
COPD and controls. Data are presented as mean¡SD. A two-
tailed probability value of v0.05 was considered statistically
significant.
Results
Subject characteristics are shown in table 1. There were no
differences in sex or age between the groups. FFMI was
significantly lower in COPD patients than in controls, despite
a similar BMI. Isokinetic leg power was significantly lower in
COPD patients than in controls, at both speeds. Handgrip
strength was also lower in COPD patients compared with
healthy subjects. The proportions of type-I fibres (fibres with
high oxidative capacity) were markedly lower in COPD
patients, whereas the fibre type-IIX proportion was higher
compared with healthy subjects. Fibre-type IIX CSA was
significantly smaller in COPD patients.
Frequencies of the severity scores in controls versus COPD
patients are shown in table 2. No scoresw2 for severity (on a
scale of 0–5) were obtained for any of the semiquantitatively





Age yrs 64¡3 67¡9
BMI kg?m-2 26.3¡3.3 23.9¡4.0
FFM kg 58.2¡9.0 48.8¡6.9**
FFMI kg?m-2 19.6¡2.2 17.2¡1.7**
FEV1 % pred 109¡17.2 42¡13.9***
Pa,O2 kPa 11.8¡1.6 9.9¡1.2***
DL,CO % pred 123¡23 63¡24***
RV % pred 114¡15 167¡32***
ITGV % pred 108¡17 144¡22***
Muscle function
Leg power at 20 cm?s-1 W 265¡62 203¡88*
Leg power at 60 cm?s-1 W 561¡154 363¡145**
Handgrip strength kg 43¡8 31¡8***
Muscle biopsy
Proportion of type-I fibres % 43.4¡12.6 19.4¡14.0***
Proportion of type-IIA fibres % 29.4¡12.1 34.8¡11.9
Proportion of type-IIX fibres % 27.2¡12.3 45.8¡18.9***
CSA of type-IIX fibres mm2 4248¡1300 2566¡1137**
Data are presented as mean¡SD. M: male; F: female; BMI: body mass
index; FFM: fat-free mass; FFMI: fat-free mass index; FEV1: forced
expiratory volume in one second; % pred; % predicted; Pa,O2: arterial
oxygen tension; DL,CO: diffusion capacity for carbon monoxide; RV:
residual volume; ITGV: intrathoracic gas volume; CSA: cross-sectional
area. Significance of difference compared with controls. *: pv0.05; **:
pv0.01; ***: pv0.001. Control: n=16; COPD: n=15.
Table 2. – Severity score frequencies of myopathological features
Pathological feature Severity score p-value
0 1 2
Control COPD Control COPD Control COPD
Atrophied fibres 8 1 8 5 0 9 v0.001
Hypertrophied fibres 15 10 1 5 0 0
Fibre type grouping 4 5 11 9 1 1
Fibre splitting 13 13 3 2 0 0
Fibrosis perimysial 12 10 4 2 0 3
Fibrosis endomysial 8 1 8 14 0 0 v0.01
Fat cells 12 8 3 6 1 1
Inflammatory cells 16 12 0 3 0 0
Central nuclei 15 13 1 2 0 0
Necrotising fibres 16 12 0 3 0 0
Regenerating fibres 13 8 3 7 0 0
Cores 16 15 0 0 0 0
Moth-eaten fibres 16 12 0 3 0 0
Targets 16 15 0 0 0 0
Hyaline fibres 16 15 0 0 0 0
Ring fibres 16 14 0 1 0 0
Data are presented as n. Frequencies for severity scores 3–5 are not shown, since none of the subjects had scoresw2 for any of the features. Atrophy
and hypertrophy: abnormal fibre size and/or shape; fibre-type grouping: replacement of the normal mosaic pattern by groups of histochemically
uniform fibre types; inflammatory cells: macrophages and leukocytes; cores: zones devoid of oxidative enzyme activity staining; moth-eaten: patchy
staining due to the disruption of the intermyofibrillar; targets: unreactive core surrounded by a darker staining rim; hyline fibres: rounded, heavily
haematoxylin and eosin stained fibres (due to hypercontraction of myofibrils); ring fibres: dense subsarcolemmal staining. Significance of difference
compared to controls (based on Pearson Chi-squared). Control: n=16; COPD: n=15.
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screened myopathological features either in COPD patients or
in healthy subjects. Normal amounts of macrophages and
leukocytes were found, randomly scattered between fibres in
control subjects as well as in COPD patients. There were no
clear signs of excessive necrosis and/or regeneration in either
group. There were no signs of mitochondrial or cytoskeletal
rearrangements, such as moth-eaten fibres, cores, target
fibres, hyaline fibres or ring fibres (apart from the higher
proportion of fibres deficient for COX and SDH in COPD) in
either group. In both patients and controls a mild replacement
of muscle by fat cells and fibrotic material was observed
(fig. 1a and b), the latter being slightly more pronounced in
COPD patients (Chi-squared=7.06; p=0.008). Atrophy of
muscle fibres was clearly more pronounced in COPD patients
(Chi-squared=15.12; p=0.001). In both groups, the atrophied
fibres were randomly scattered and mainly had angulated
shapes (fig. 1c), although rounded fibres were also observed.
The roundness of type-IIX fibres was also assessed, and was





Fig. 1. – a) Van Gieson stain showing increased amounts of connective tissue (collagen stains red). Both perimysial and endomysial fibrosis is
present. b) Haematoxylin-eosin stain showing fat cell replacement. The fat cells appear as "holes", because of lack of staining. c) Myofibrillar
adenosine triphosphatease stain (double pre-incubation at pH 10.4 followed by 4.6) showing small and angulated dark fibres that are atrophied
type-IIX fibres. Note the large variation in fibre sizes. d) Representative transferase deoxyuridine triphosphate nick-end labelling (TUNEL) stain
of a healthy control. e) Representative TUNEL stain of a chronic obstructive pulmonary disease (COPD) patient. f) Positive control for
TUNEL staining (a deoxyribonucleic acid I streated section). g) Representative caspase 3 stain of a healthy control. h) Representative caspase 3
stain of a COPD patient. i) Positive control for caspase 3 staining (a human malignant sarcoma). Internal scale bars=100 mm.
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DNA fragmentation was assessed with TUNEL staining
(fig. 1d–f). The proportion of positive nuclei was not different
between controls and COPD patients (1.1¡1.6% versus
1.0¡0.8%). The proportion of TUNEL-positive nuclei did
not correlate with fibre CSA or with FFM in COPD patients
or controls. The presence of active caspase 3 as a marker of
apoptosis was also examined, but positive fibres were absent
in both groups (fig. 1g–i).
Altogether, seven of the 15 COPD patients were on a
maintenance dose of prednisolone during the study. However,
there were no differences for any of the myopathological
features examined in the current study between the patients
who received corticosteroids and nonreceivers. Also, the pro-
portion of TUNEL-positive nuclei was not different between
receivers and nonreceivers (1.1¡0.8% versus 0.9¡0.9%,
respectively).
Discussion
In this study the "classical" myopathological features in the
vastus lateralis of healthy controls and patients with COPD
was assessed. The COPD patients had reduced muscle mass
and suffered from muscle weakness. Compared with healthy
age-matched controls, a I to IIX shift in fibre types and
marked fibre-type IIX atrophy was present as reported
previously [13, 14]. There were no other clear morphological
differences between controls and patients, except for a slight
increase of intramuscular fibrosis and fat-cell replacement in
COPD. This can probably be explained by the higher degree
of fibre atrophy in the patients, since the presence of increased
connective tissue and fat cells is common for the severely
atrophying muscle [6]. Indeed, some degree of fibrosis and
fatty cell replacement is not uncommon for the skeletal
muscle of the elderly, which is probably associated with the
age-related atrophy of type-II fibres [16]. The observation of
rounded fibres secondary to angulated fibres, suggests that the
observed muscle atrophy is slowly progressing and long-
standing. Therefore, the abnormalities found can probably be
attributed to the general pathology in the elderly, for example
caused by physical inactivity or microangiopathy. Micro-
angiopathy in peripheral neuropathy (examined in nerve
biopsies) has been reported for COPD and the involvement of
hypoxia was suggested [17]. OZGE et al. [18] also found a
correlation between the degree of neuropathy (functionally
assessed) and hypoxaemia in COPD. However, patients in the
current study were not extremely hypoxic and it is therefore
worth examining these myopathological features in patients
with severe hypoxaemia.
The specific form of fibre-type IIX atrophy excludes a
predominant involvement of physical inactivity, because a
more generalised, nonfibre type specific atrophy would be
expected [6, 7]. DECRAMER et al. [19] showed selective fibre
type-II atrophy in COPD patients with diagnosed steroid-
induced myopathy. In that study affected fibres were also
angulated and increased connective tissue was observed. In
contrast to their data, no increase in numbers of necrotic
fibres and central nuclei was found in this study. Further-
more, no differences were found between COPD patients who
received (low doses of) prednisolone and those who did not.
The authors also had no previous evidence for the involve-
ment of corticosteroids in fibre type-IIX atrophy [14].
The aetiology of fibre type-IIX atrophy is still not
understood completely, but its involvement in the loss of
muscle mass and, hence, its effect on muscle strength in
COPD is obvious [14]. Although the COPD patients in the
current study were not cachectic, they were characterised by a
reduced FFMI relative to the control group. Atrophy may
not be the only factor that is associated with the loss of muscle
mass. Necrosis and apoptosis (i.e. "programmed" cell death)
are two other processes that may lead to the reduction of
muscle mass through the disappearance of muscle cells. The
present data suggest that necrosis is not involved, which is
underscored by the fact that the authors did not observe any
widespread infiltrates of immune cells that normally accom-
pany necrosis [20]. The authors found that only y1% of all
myocyte nuclei was TUNEL-positive, for controls as well as
for COPD patients. However, using TUNEL for the detection
of apoptosis should be interpreted with caution, since
nonspecific DNA fragmentation may also be detected [21].
Therefore, the authors also immunostained for active caspase
3, an established marker for apoptosis [21], and in neither
controls nor patients cytoplasmatic immunostaining for
active caspase 3 was found. The data in the current study
thus suggest that apoptosis of muscle fibres does not occur,
certainly not to a higher degree in COPD patients compared
with controls. However, despite the authors reservations
regarding the TUNEL data, few positive nuclei in COPD
patients as well as in healthy subjects were found. Since
myocytes are multi-nucleated, apoptotic nuclei may well be
important to adjust the number of myonuclei in fibres during
atrophying conditions [22]. A relationship between fibre CSA
and the number of TUNEL-positive myonuclei has indeed
been shown in chronic heart failure [23]. However, the
authors did not find this relationship in COPD, which may be
related to the low frequency of TUNEL-positivity or because
the patients in the current study were in a weight-stable
condition and may be less underweight. Alternatively, since
apoptosis is a very dynamic process and the progress of
muscle wasting is relatively slow, very small differences may
be expected between patients and controls. Therefore, it is
possible that the current methodology is not sufficient to
detect those potential differences.
Muscle wasting has convincingly been associated with
systemic inflammation in COPD [24–26]. Also, it is feasible
that circulating inflammatory cells infiltrate into the muscle in
a similar way to bronchial inflammatory cell infiltration.
Therefore, the presence of inflammatory cells in the wasting
muscle can be expected. However, the authors did not find
abnormal numbers of macrophages and leukocytes in the
muscle tissue of COPD patients. This indicates that intra-
muscular inflammatory cells are most likely not the source of
inflammatory mediators that affect the muscle. It should be
noted that there is a small probability that magnitude of
inflammatory cell infiltration into the muscle could have been
reduced by corticosteroid administration. However, as
discussed above, only one-half of the patients received this
medication and the doses were low. Alternatively, circulating
cytokines and chemokines or mediators produced by local
endothelial cells or even the myocytes themselves, may be
involved in the association between inflammation and skeletal
muscle wasting. However, this assumption requires further
investigation, which was beyond the scope of the present study.
In summary, this is the first time that peripheral muscle
weakness in chronic obstructive pulmonary disease has been
approached from a myopathological perspective using a
broad set of standard histochemical techniques. Apart from
the marked fibre type-IIX atrophy in chronic obstructive
pulmonary disease, the results show little difference between
patients with chronic obstructive pulmonary disease and
healthy age-matched control subjects. In addition to the I to
IIX shift in fibre types and selective type-IIX atrophy in
chronic obstructive pulmonary disease, a slight increase in
fibrosis and fat-cell replacement, which probably accompa-
nies the fibre atrophy, was observed in these patients. No
other clear features of muscle pathologies were observed, nor
was there an increase in the amount of intramuscular
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inflammatory cells. Furthermore, there were no indications
that necrosis and apoptosis are involved in muscle pathology.
Future studies are required to determine potential differences
in muscle pathology in the subgroups of severe hypoxic
patients and cachectic chronic obstructive pulmonary disease
patients (characterised by weight loss and disproportionate
wasting of fat-free mass) and to further describe the
mechanisms underlying skeletal muscle fibre atrophy.
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